BACKGROUND: The current retrospective study aims to identify some determinants of survival in metastatic breast cancer. METHODS: The study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0-1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates. RESULTS: Overall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age ≤ 70 years, hormono-dependence of the tumor, good PS (PS 0-1), less than two metastatic sites, no visceral metastases, DFI ≥ 24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0-1), absence of visceral metastases (liver, lung, brain) and age ≤ 70 years. CONCLUSION: Many of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials.
BACKGROUND: The current retrospective study aims to identify some determinants of survival in metastatic breast cancer. METHODS: The study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0-1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates. RESULTS: Overall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age ≤ 70 years, hormono-dependence of the tumor, good PS (PS 0-1), less than two metastatic sites, no visceral metastases, DFI ≥ 24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0-1), absence of visceral metastases (liver, lung, brain) and age ≤ 70 years. CONCLUSION: Many of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials.
Entities:
Keywords:
Breast cancer; Metastasis; Prognostic factors; Survival
Authors: J Aisner; C Cirrincione; M Perloff; M Perry; D Budman; J Abrams; L Panasci; H Muss; M Citron; J Holland Journal: J Clin Oncol Date: 1995-06 Impact factor: 44.544
Authors: L Bastholt; M Dalmark; S B Gjedde; P Pfeiffer; D Pedersen; E Sandberg; M Kjaer; H T Mouridsen; C Rose; O S Nielsen; P Jakobsen; S M Bentzen Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: Roshni Rao; Lei Feng; Henry M Kuerer; S Eva Singletary; Isabelle Bedrosian; Kelly K Hunt; Merrick I Ross; Gabriel N Hortobagyi; Barry W Feig; Frederick C Ames; Gildy V Babiera Journal: Ann Surg Oncol Date: 2008-03-21 Impact factor: 5.344
Authors: Ram Eitan; Mary L Gemignani; Ennapadam S Venkatraman; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2003-08 Impact factor: 5.482
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig C Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam Journal: Breast Cancer Res Treat Date: 2018-06-01 Impact factor: 4.872
Authors: Rameshwar Patil; Alexander V Ljubimov; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Shawn Wagner; Satoshi Inoue; Bindu Konda; Arthur Rekechenetskiy; Alexandra Chesnokova; Janet L Markman; Vladimir A Ljubimov; Debiao Li; Ravi S Prasad; Keith L Black; Eggehard Holler; Julia Y Ljubimova Journal: ACS Nano Date: 2015-05-06 Impact factor: 15.881
Authors: Rameshwar Patil; Yosef Koronyo; Alexander V Ljubimov; Brenda Salumbides; Adam Mamelak; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Eggehard Holler; Pramod Butte; Maya Koronyo-Hamaoui; Julia Y Ljubimova; Keith L Black Journal: Bangk Med J Date: 2015-09
Authors: Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam Journal: Breast Cancer Res Treat Date: 2016-06-24 Impact factor: 4.872
Authors: Daniel M Sciubba; C Rory Goodwin; Alp Yurter; Derek Ju; Ziya L Gokaslan; Charles Fisher; Laurence D Rhines; Michael G Fehlings; Daryl R Fourney; Ehud Mendel; Ilya Laufer; Chetan Bettegowda; Shreyaskumar R Patel; Y Raja Rampersaud; Arjun Sahgal; Jeremy Reynolds; Dean Chou; Michael H Weber; Michelle J Clarke Journal: Global Spine J Date: 2015-10-21